801 related articles for article (PubMed ID: 31539778)
1. New oxadiazoles with selective-COX-2 and EGFR dual inhibitory activity: Design, synthesis, cytotoxicity evaluation and in silico studies.
El-Sayed NA; Nour MS; Salem MA; Arafa RK
Eur J Med Chem; 2019 Dec; 183():111693. PubMed ID: 31539778
[TBL] [Abstract][Full Text] [Related]
2. Rational design-aided discovery of novel 1,2,4-oxadiazole derivatives as potential EGFR inhibitors.
Unadkat V; Rohit S; Parikh P; Sanna V; Singh S
Bioorg Chem; 2021 Sep; 114():105124. PubMed ID: 34328857
[TBL] [Abstract][Full Text] [Related]
3. In Vitro and In Silico Evaluation of Anticancer Activity of New Indole-Based 1,3,4-Oxadiazoles as EGFR and COX-2 Inhibitors.
Sever B; Altıntop MD; Özdemir A; Akalın Çiftçi G; Ellakwa DE; Tateishi H; Radwan MO; Ibrahim MAA; Otsuka M; Fujita M; Ciftci HI; Ali TFS
Molecules; 2020 Nov; 25(21):. PubMed ID: 33171861
[TBL] [Abstract][Full Text] [Related]
4. Design and synthesis of benzimidazole analogs endowed with oxadiazole as selective COX-2 inhibitor.
Rathore A; Rahman MU; Siddiqui AA; Ali A; Shaharyar M
Arch Pharm (Weinheim); 2014 Dec; 347(12):923-35. PubMed ID: 25303727
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis and biological evaluation of novel indanone containing spiroisoxazoline derivatives with selective COX-2 inhibition as anticancer agents.
Abolhasani H; Zarghi A; Komeili Movahhed T; Abolhasani A; Daraei B; Dastmalchi S
Bioorg Med Chem; 2021 Feb; 32():115960. PubMed ID: 33477020
[TBL] [Abstract][Full Text] [Related]
6. Design, Synthesis,
Matada GSP; Abbas N; Dhiwar PS; Basu R; Devasahayam G
Anticancer Agents Med Chem; 2021; 21(4):451-461. PubMed ID: 32698735
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis and biological evaluation of a new series of thiazolyl-pyrazolines as dual EGFR and HER2 inhibitors.
Sever B; Altıntop MD; Radwan MO; Özdemir A; Otsuka M; Fujita M; Ciftci HI
Eur J Med Chem; 2019 Nov; 182():111648. PubMed ID: 31493743
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis and anticancer evaluation of thieno[2,3-d]pyrimidine derivatives as dual EGFR/HER2 inhibitors and apoptosis inducers.
Elmetwally SA; Saied KF; Eissa IH; Elkaeed EB
Bioorg Chem; 2019 Jul; 88():102944. PubMed ID: 31051400
[TBL] [Abstract][Full Text] [Related]
9. Discovery of novel pyrazole based Urea/Thiourea derivatives as multiple targeting VEGFR-2, EGFR
Fadaly WAA; Nemr MTM; Kahk NM
Bioorg Chem; 2024 Jun; 147():107403. PubMed ID: 38691909
[TBL] [Abstract][Full Text] [Related]
10. In silico design, synthesis and activity of potential drug-like chrysin scaffold-derived selective EGFR inhibitors as anticancer agents.
Debnath S; Kanakaraju M; Islam M; Yeeravalli R; Sen D; Das A
Comput Biol Chem; 2019 Dec; 83():107156. PubMed ID: 31710991
[TBL] [Abstract][Full Text] [Related]
11. 1,3,4-oxadiazole/chalcone hybrids: Design, synthesis, and inhibition of leukemia cell growth and EGFR, Src, IL-6 and STAT3 activities.
Fathi MAA; Abd El-Hafeez AA; Abdelhamid D; Abbas SH; Montano MM; Abdel-Aziz M
Bioorg Chem; 2019 Mar; 84():150-163. PubMed ID: 30502626
[TBL] [Abstract][Full Text] [Related]
12. Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme.
El-Helby AA; Sakr H; Ayyad RRA; El-Adl K; Ali MM; Khedr F
Anticancer Agents Med Chem; 2018; 18(8):1184-1196. PubMed ID: 29651967
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis, in vitro and in silico evaluation of a new series of oxadiazole-based anticancer agents as potential Akt and FAK inhibitors.
Altıntop MD; Sever B; Akalın Çiftçi G; Turan-Zitouni G; Kaplancıklı ZA; Özdemir A
Eur J Med Chem; 2018 Jul; 155():905-924. PubMed ID: 29966916
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis, chemical characterization, biological evaluation, and docking study of new 1,3,4-oxadiazole homonucleoside analogs.
El Mansouri AE; Maatallah M; Ait Benhassou H; Moumen A; Mehdi A; Snoeck R; Andrei G; Zahouily M; Lazrek HB
Nucleosides Nucleotides Nucleic Acids; 2020; 39(8):1088-1107. PubMed ID: 32397827
[TBL] [Abstract][Full Text] [Related]
15. New pyrimidine and pyrazole-based compounds as potential EGFR inhibitors: Synthesis, anticancer, antimicrobial evaluation and computational studies.
Othman IMM; Alamshany ZM; Tashkandi NY; Gad-Elkareem MAM; Anwar MM; Nossier ES
Bioorg Chem; 2021 Sep; 114():105078. PubMed ID: 34161878
[TBL] [Abstract][Full Text] [Related]
16. Novel Phenolic Compounds as Potential Dual EGFR and COX-2 Inhibitors: Design, Semisynthesis, in vitro Biological Evaluation and in silico Insights.
Abdelgawad MA; Musa A; Almalki AH; Alzarea SI; Mostafa EM; Hegazy MM; Mostafa-Hedeab G; Ghoneim MM; Parambi DGT; Bakr RB; Al-Muaikel NS; Alanazi AS; Alharbi M; Ahmad W; Bukhari SNA; Al-Sanea MM
Drug Des Devel Ther; 2021; 15():2325-2337. PubMed ID: 34103896
[TBL] [Abstract][Full Text] [Related]
17. New Ferrocene Compounds as Selective Cyclooxygenase (COX-2) Inhibitors: Design, Synthesis, Cytotoxicity and Enzyme-inhibitory Activity.
Farzaneh S; Zeinalzadeh E; Daraei B; Shahhosseini S; Zarghi A
Anticancer Agents Med Chem; 2018; 18(2):295-301. PubMed ID: 28971779
[TBL] [Abstract][Full Text] [Related]
18. Design and Synthesis of some new 2,4,6-trisubstituted quinazoline EGFR inhibitors as targeted anticancer agents.
Allam HA; Aly EE; Farouk AKBAW; El Kerdawy AM; Rashwan E; Abbass SES
Bioorg Chem; 2020 May; 98():103726. PubMed ID: 32171987
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and anticancer evaluation of 1H-pyrazolo[3,4-d]pyrimidine derivatives as potent EGFR
Gaber AA; Bayoumi AH; El-Morsy AM; Sherbiny FF; Mehany ABM; Eissa IH
Bioorg Chem; 2018 Oct; 80():375-395. PubMed ID: 29986185
[TBL] [Abstract][Full Text] [Related]
20. Novel benzothiazole-based dual VEGFR-2/EGFR inhibitors targeting breast and liver cancers: Synthesis, cytotoxic activity, QSAR and molecular docking studies.
Abd El-Meguid EA; Naglah AM; Moustafa GO; Awad HM; El Kerdawy AM
Bioorg Med Chem Lett; 2022 Feb; 58():128529. PubMed ID: 35007724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]